Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination-Reference-Cited by-同舟云学术

Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination

Published:2023-07-18 Issue:4 Volume:111 Page:668-670
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Callegari Chiara¹^ORCID,Lazzarotto Davide¹,Soravia Alessandra¹,Mutti Martina²,Lauzzana Pietro¹,Peghin Maddalena³,Cordella Stefano²,Fanin Renato¹,Candoni Anna¹²

Affiliation:

1. Division of Hematology and Stem Cell Transplantation Unit Azienda Sanitaria Universitaria Friuli Centrale Udine Italy

2. Division of Hematology, Department of Medical and Surgical Sciences University of Modena and Reggio Emilia Modena Italy

3. Division of Infectious Diseases Azienda Sanitaria Universitaria Friuli Centrale Udine Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.14045

Reference12 articles.

1. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

2. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

3. Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax

4. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

5. COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation;Infectious Agents and Cancer;2024-08-12